[Antithrombotic agents in acute myocardial infarction].
Coronary thrombosis, which is responsible for myocardial infarction, is a complex phenomenon involving the interaction of the arterial wall, the coagulation system and the platelets. Better understanding of the molecular biology of thrombosis has led to the rapid development of antithrombotic therapy. The limitations of aspirin and heparin have promoted the development of new molecules whose site of action on platelets or at different stages of coagulation are known. Some of them are the object of large scale international trials. Some results have been disappointing such as those with the direct antithrombins: others are promising and in the phase of evaluation, such as the inhibitors of glycoproteins GP IIb-IIIa.
Boschat
J
J
Département de cardiologie, hôpital de la Cavale Blanche, CHU Brest.
Larlet
J M
JM
Gilard
M
M
D000925:Anticoagulants / Q000627:therapeutic use*; D000991:Antithrombins / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D016023:Integrins / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*
D000925:Anticoagulants; D000991:Antithrombins; D016023:Integrins; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D001241:Aspirin